CA
NBIX icon

Clearstead Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Clearstead Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.1K Sell
345
-1,974
-85% -$293K ﹤0.01% 1455
2026
Q1 		$306K Sell
2,319
-766
-25% -$102K ﹤0.01% 852
2025
Q4 		$438K Buy
3,085
+1,771
+135% +$257K 0.01% 694
2025
Q3 		$184K Buy
1,314
+582
+80% +$78.9K ﹤0.01% 900
2025
Q2 		$92K Buy
732
+376
+106% +$43.1K ﹤0.01% 1090
2025
Q1 		$39.4K Buy
356
+43
+14% +$5.45K ﹤0.01% 1231
2024
Q4 		$42.7K Buy
313
+5
+2% +$618 ﹤0.01% 1202
2024
Q3 		$35.5K Sell
308
-440
-59% -$60.3K ﹤0.01% 1281
2024
Q2 		$103K Buy
748
+285
+62% +$39.1K ﹤0.01% 992
2024
Q1 		$63K Sell
463
-45
-9% -$6.15K ﹤0.01% 712
2023
Q4 		$66.9K Sell
508
-22
-4% -$2.53K ﹤0.01% 675
2023
Q3 		$59.6K Buy
530
+53
+11% +$5.58K ﹤0.01% 661
2023
Q2 		$45K Buy
477
+247
+107% +$24.1K ﹤0.01% 747
2023
Q1 		$23.3K Buy
+230
New +$23.9K ﹤0.01% 820

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Advisors's NBIX Position: Q2 2026 in Review

Clearstead Advisors reduced its Neurocrine Biosciences (NBIX) stake by 85% in Q2 2026, selling an estimated $293K and leaving 345 shares worth $58.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1455.

Clearstead Advisors first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. The position peaked at $438K in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Clearstead Advisors held 345 shares of Neurocrine Biosciences worth $58.1K as of Q2 2026.
  • Clearstead Advisors sold 1,974 Neurocrine Biosciences shares in Q2 2026, an estimated $293K.
  • Neurocrine Biosciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1455 holding.
  • Clearstead Advisors first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
  • Clearstead Advisors's Neurocrine Biosciences position peaked at $438K in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.